Valuation
- Market cap
- 3,192,813,000
- Revenue TTM
- $0
- Net income TTM
- $-177,040,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 1,316,000
- Avg volume
- 1,271,028
- Day's range
- $63.49 – $66.30
- Shares out
- 48,932,000
- Stochastic %K
- 87%
- Beta
- 0.10
- Analysts
- Strong Sell
- Price target
- $155.50
Company profile
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients wi...
Show more
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- (763) 392-0123
- Website
- https://www.celcuity.com
- Address
- 2800 Campus Drive, Suite 140, Minneapolis, United States
Latest news
No headlines yet.
